Novel Targets for Solid Tumors. First-in-Class Cancer Therapeutics.
DEM BioPharma is a clinical-stage biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class cancer therapeutics. The company's lead program, DEM301, is an antibody-drug conjugate (ADC) targeting a novel innate immune checkpoint pathway. DEM Bio's approach focuses on unleashing macrophages and immune phagocytes to eliminate tumors by targeting 'don't eat me' (DEM) signals — a distinct mechanism from conventional checkpoint inhibitors. Headquartered in Cambridge, Massachusetts, DEM Bio was founded in 2022 and is backed by a world-class scientific and operating team.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2022
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
